期刊
CHEMISTRYSELECT
卷 3, 期 1, 页码 176-187出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/slct.201702295
关键词
Histone deacetylases (HDACs) 1; immunosuppressant 2; organ transplantation
资金
- National Key R&D Program of China [2017YFC1103704]
- Sanming Project of Medicine in Shenzhen [SZSM201412020]
- Fund for High Level Medical Discipline Construction of Shenzhen [2016031638]
- Shenzhen Foundation of Science and Technology [JCJY20160229204849975, GJHZ20170314171357556, JCYJ20170306091928754]
- Shenzhen Foundation of Health and Family Planning Commission [SZXJ2017021, SZBC2017028]
- China Postdoctoral Science Foundation [2017 M612790]
Immune rejection is the major obstacle to graft survival and quality of life of recipients after organ transplantation. The immunosuppressants applied in clinical face severe safety and efficacy issues. Histone deacetylases (HDACs) are emerging novel drug targets in the treatment of malignancies and immune disorders. HDAC inhibitors show potential as valuable immune regulators after allo- or xeno-organ transplantation. However, studies that evaluate HDAC inhibitors and mechanisms are still limited. In this review, we focused on the immunomodulatory effects of HDAC inhibitors in transplantation. Finally, we discussed the implications and challenges of applying HDAC inhibitors in allo- and xeno-transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据